The access to medicine index 2014

A new study by the Access to Medicine Foundation identifies promise in the vaccine pipeline from the world’s largest pharmaceutical companies. Certain vaccine candidates are clearly supported by plans for facilitating their future accessibility, yet such planning ahead for access does not appear to be consistent or widespread.

In the new study, the Access to Medicine Foundation has analysed the vaccine pipelines of the 20 companies measured by the 2014 Access to Medicine Index. The study investigates which vaccines are being developed by large pharmaceutical companies for high-burden diseases; and assesses whether these companies use access provisions (such as price caps or supply commitments) to help ensure the future accessibility of the vaccine candidates in their pipelines.